The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...
One of the first no-brainer dividend stocks to buy with $100 right now is AT&T. At recent prices, America's second-largest telecommunications business by revenue offers a juicy 5.1% dividend yield.
Hosted on MSN2d
US FDA approves new schizophrenia drugThe US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback